In Case You Missed It: "Improving the diagnosis of Lyme disease: See who you could be missing with ZEUS Borrelia MTTT"

Fill out the form to watch it on-demand.

A review and discussion of the enhanced sensitivity of the ZEUS Borrelia Modified Two-Tiered Testing (MTTT) algorithm in detecting early Lyme disease as compared to the Standard Two-Tiered Testing (STTT) algorithm. If you are still using STTT learn how you can start detecting nearly double the number of early cases (stage 1 & 2) of Lyme disease with ZEUS MTTT and eliminate the need for immunoblots.

Presented by

Ron Cruver

Business Line Manager-Vector Borne Diseases

Sebia Autoimmune & Infectious Diseases

Biography

Ron Cruver manages ZEUS’s Vector-Borne Disease Business Line and joined the company in 2020. Ron brings over 30 years of industry experience working with in vitro diagnostic medical devices. He specializes in infectious disease serology testing with an emphasis Lyme disease testing. Ron has a bachelor’s degree in Recombinant Gene Technology from the State University of New York at Fredonia.

Sign up for on-demand access!

ZEUS Borrelia MTTT^® Advantages

The all-ELISA algorithm is the simple, sensitive, and specific alternative that is changing the game in Lyme disease testing.

• Reduces the number of missed clinically positive patient samples, especially in early Lyme disease (stages 1 and 2) 
• Removes the burden of Western blots and subjectivity of reading and interpreting immunoblots   
• Enables simple and flexible first-tier and second-tier testing in-house 
• Improves overall lab workflow and cost efficiencies, eliminating send-outs 
• Improves turnaround time  

If you are still running Lyme disease immunoblots in your laboratory, take a look at the clinical data to see how ZEUS Borrelia MTTT improves detection in early Lyme disease.

Simplify your testing. Contact ZEUS today or visit zeuslyme.com to learn more.